Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
We have previously shown that absence of the mouse mdr1a (also called mdr3) P-glycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds. We show here that the mouse mdr1a and the human MDR1 P-glycoprotein actively transport ivermectin, dexamethasone, digoxin, and cyclosporin A and, to a lesser extent, morphine across a polarized kidney epithelial cell layer in vitro. Injection of these radio-labeled drugs in mdr1a (-/-) and wild-type mice resulted in markedly (20- to 50-fold) higher levels of radioactivity in mdr1a (-/-) brain for digoxin and cyclosporin A, with more moderate effects for dexamethasone (2- to 3-fold) and morphine (1.7-fold). Digoxin and cyclosporin A were also more slowly eliminated from mdr1a (-/-) mice. Our findings show that P-glycoprotein can be a major determinant for the pharmacology of several medically important drugs other than anti-cancer agents, especially in the blood-brain barrier. These results may explain a range of pharmacological interactions observed between various drugs in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Self-citationTHE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Cited by
Items 101–141 of 141
Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E., & Sugiyama, Y. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162321 · Cited by 266
Methodological issues in microdialysis sampling for pharmacokinetic studies
de Lange, E. C. M., de Boer, A. G., & Breimer, D. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00107-1 · Cited by 264
Evers, R., Zaman, G. J., van Deemter, L., Jansen, H., Calafat, J., Oomen, L. C., Oude Elferink, R. P., Borst, P., & Schinkel, A. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118535 · Cited by 260
Self-citationHebert, M., Easterling, T., Kirby, B., Carr, D., Buchanan, M., Rutherford, T., Thummel, K., Fishbein, D., & Unadkat, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.1 · Cited by 259
Blood-brain barrier transport machineries and targeted therapy of brain diseases
Barar, J., Rafi, M. A., Pourseif, M. M., & Omidi, Y. (2016) · BioImpacts · doi:10.15171/bi.2016.30 · Cited by 257
MDR- and CYP3A4-mediated drug–herbal interactions
Pal, D., & Mitra, A. K. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.010 · Cited by 254
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Pharmacokinetic Interactions of Drugs with St John’s Wort
Zhou, S., Chan, E., Pan, S.-Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 253
Smith, A. J., van Helvoort, A., van Meer, G., Szabó, K., Welker, E., Szakács, G., Váradi, A., Sarkadi, B., & Borst, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909002199 · Cited by 252
Self-citationOmidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., & Gumbleton, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03443-7 · Cited by 246
Hellinger, É., Veszelka, S., Tóth, A. E., Walter, F., Kittel, Á., Bakk, M. L., Tihanyi, K., Háda, V., Nakagawa, S., Dinh Ha Duy, T., et al. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.07.020 · Cited by 237
The brain mineralocorticoid receptor: greedy for ligand, mysterious in function
Reul, J. M. H. M., Gesing, A., Droste, S., Stec, I. S. M., Weber, A., Bachmann, C., Bilang-Bleuel, A., Holsboer, F., & Linthorst, A. C. E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00677-4 · Cited by 227
“In addition, the Žmdr1a P-glycoprotein, although present in the kidney see .references in Schinkel et al., 1995 , does not seem to Žremove dexamethasone from this organ Schinkel et al., .1995 .”
Backgroundde Lange, E. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00014-3 · Cited by 226
Baltes, S., Gastens, A. M., Fedrowitz, M., Potschka, H., Kaever, V., & Löscher, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.038 · Cited by 223
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220
Drug transport proteins in the liver
Faber, K. N., Müller, M., & Jansen, P. L. M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00173-4 · Cited by 220
Kang, J.-E., Cirrito, J. R., Dong, H., Csernansky, J. G., & Holtzman, D. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700148104 · Cited by 219
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180240 · Cited by 216
“LLC-PK1 wild-type and MDR1-overexpressing L-MDR1 cells (Schinkel et al., 1995) were purchased from the Dutch Cancer Institute (Amsterdam, The Netherlands).”
MethodDendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators
Randolph, G. J. (2001) · Seminars in Immunology · doi:10.1006/smim.2001.0322 · Cited by 211
Jamroziak, K., Młynarski, W., Balcerczak, E., Mistygacz, M., Treliǹska, J., Mirowski, M., Bodalski, J., & Robak, T. (2004) · European Journal of Haematology · doi:10.1111/j.1600-0609.2004.00228.x · Cited by 194
“central nervous system (CNS), and elimination with urine and bile (10, 11).”
BackgroundInfluentialCharacterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192
Salama, N. N., Yang, Z., Bui, T. O. T., & Ho, R. J. Y. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20717 · Cited by 189
Functional expression and localization of P‐glycoprotein at the blood brain barrier
Bendayan, R., Lee, G., & Bendayan, M. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10090 · Cited by 187
“Similar to their human counterparts, murine P-gp encoded by mdr1a/b confers the MDR phenotype (Gros et al., 1986; Schinkel et al., 1994, 1995; Ueda et al., 1987) whereas the mdr2 gene product serves in the transport of hepatic phospholipids into the bile (Smit et al., 1993).”
BackgroundAn oncological view on the blood–testis barrier
Bart, J., Groen, H. J., van der Graaf, W. T., Hollema, H., Hendrikse, N. H., Vaalburg, W., Sleijfer, D. T., & de Vries, E. G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00776-3 · Cited by 183
Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism
Eichelbaum, M., Fromm, M. F., & Schwab, M. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00017 · Cited by 176
“For many drugs Pgp expressed at the luminal site of the endothelial cells of the brain capillaries drastically limits the transfer from blood into the brain, as evidenced by the 35-fold increase in brain-to-blood concentration ratio of digoxin in the mdr1a-knockout mice versus control animals.(18) Because many CNS-act…”
BackgroundCarrier-mediated or specialized transport of drugs across the blood–brain barrier
Tsuji, A., & Tamai, I. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00084-2 · Cited by 174
Blood−brain barrier transporters and response to CNS-active drugs
Urquhart, B. L., & Kim, R. B. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0714-8 · Cited by 174
“Cetirizine [48] ↓ Cyclosporin A [ 49 ] ↓ Digoxin [49] ↓”
Therapeutic implications of the MDR‐1 gene
Mealey, K. L. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00607.x · Cited by 172
Does inhibition of P-glycoprotein lead to drug–drug interactions?
Balayssac, D., Authier, N., Cayre, A., & Coudore, F. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2004.12.008 · Cited by 171
Camenisch, G., Folkers, G., & van de Waterbeemd, H. (1996) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(96)00031-3 · Cited by 169
Clinical Relevance of P-Glycoprotein in Drug Therapy
Lin, J. H., & Yamazaki, M. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026871 · Cited by 167
“…(17- and 55-fold, respectively) were observed in mdr1a ( / ) mice compared with mdr1a (þ/þ) mice, whereas only a moderate increase in radioactivity levels (two- to threefold) of these two drugs was observed for liver, kidney, small intestine, and plasma of mdr1a ( / ) mice (Schinkel et al., 1995).”
BackgroundPhysical activity and breast cancer risk in a cohort of young women
Rockhill, B., Willett, W. C., Hunter, D. J., Manson, J. E., Hankinson, S. E., Spiegelman, D., & Colditz, G. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1155 · Cited by 162
Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs
Lilius, T. O., Blomqvist, K., Hauglund, N. L., Liu, G., Stæger, F. F., Bærentzen, S., Du, T., Ahlström, F., Backman, J. T., Kalso, E. A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.005 · Cited by 159
P-GLYCOPROTEIN SYSTEM AS A DETERMINANT OF DRUG INTERACTIONS: THE CASE OF DIGOXIN–VERAPAMIL
VERSCHRAAGEN, M., KOKS, C. H. W., SCHELLENS, J. H. M., & BEIJNEN, J. H. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0535 · Cited by 159
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2
de Gooijer, M. C., de Vries, N. A., Buckle, T., Buil, L. C. M., Beijnen, J. H., Boogerd, W., & van Tellingen, O. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.001 · Cited by 136
“In Vitro Transport Experiments The parental LLC porcine kidney (PK1) cell line and its Mdr1a transduced subline [16] and the parental Madine Darby Canine Kidney (MDCKII) cell line and its Bcrp1 transduced subline [17] were used to establish whether temozolomide is a substrate of Mdr1a (P-gp) and Bcrp1, respectively.”
MethodGut bitter taste receptor signalling induces ABCB1 through a mechanism involving CCK
Jeon, T.-I., Seo, Y.-K., & Osborne, T. F. (2011) · Biochemical Journal · doi:10.1042/bj20110009 · Cited by 127
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Warne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700385 · Cited by 99
“Despite being noted as a P-glycoprotein inhibitor (79), CsA showed only a 16% inhibition at 100 M.”
Yadav, S., Gattacceca, F., Panicucci, R., & Amiji, M. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5008376 · Cited by 76
Pariante, C. M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.067 · Cited by 58
Metadata
- Authors
- Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-10-01
- Volume
- 96
- Issue
- 4
- Pages
- 1698-1705
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136564762
- Cited by
- 1,107
- References
- 42
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.